We're thrilled to connect with you at SNMMI! Stop by booth 1608 to discover how Oasis V3 is revolutionizing nuclear medicine departments with its array of new features. Our team is excited to showcase how V3 can propel your department to new heights and maximizing efficiency
Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer.
"...all images retrospectively on a Segami Oasis workstation."
Read the full article here 👉https://t.co/ZstRtr4chs
Prostate-specific Membrane Antigen Positron Emission Tomography as a Biomarker to Assess Treatment Response in Patients with Advanced Prostate Cancer 👇👇👇
https://t.co/QwMxY9tQ4E
Hoy hace 80 años nació la medicina nuclear! Celebramos este hito y seguimos avanzando al futuro! Hoy, queremos que las personas conozcan los beneficios de la terapia con radionúclidos. Orgulloso embajador de la Fundación Oncidium en México 🇲🇽 ⚛️☢️
@OncidiumFoundat#theranostics
Hoy continuaremos aprendiendo sobre PET PSMA y THERACNOSTICS en Cáncer de Próstata con el increíble grupo de expertos de UROTERAG LATAM 👏👏👏👏
Dr Danny Mena Cortes - Médico Nuclear
Nuclear Medicine World
#cancerprostata#psmapetct#PSMA#prostata#lutecio177
This doesn't only mean a final result of my specialty/doctorate thesis for me,but it represents my six years, my days and nights,beliefs that I am gonna do my best in nuclear medicine... I am really thankful for my mentors for endless support! @meltem caglar
#ProPSMA 54 month follow-up #EAU23 "live" @declangmurphy
✓ PSMA PET/CT N1 prognostic for failure - HR 2.1
✗ CT/BS not prognostic
= PSMA PET/CT findings significant. More and more longer term data supporting it's use.
Presented by @veerukasi Funding @MovemberAUS@PCFA@pros_tic